Grey Matters Health Positions for Growth in Expanding Alzheimer's Diagnostics Market
ORIC Pharmaceuticals Positions for Growth in Expanding Oncology Market
Alzheimer's Diagnostic Clinic Initiative Moves Forward After Financing Close
Clinical-Stage Biopharma Co. Issues New Inducement Stock Options for Growth
From Healthcare IT Vendor to AI-Driven Holding Company
Contributed Opinion
Cancer Drug Developer Shifts 70% of Spending to Research as AI Pipeline Progresses
California Pharma Co. Tests Breakthrough Cancer Drug, Cuts Death Risk 60%
US Biotech Co. Targets Muscular Dystrophy with First-In-Class Drug
Capricor Therapeutics Inc.'s (CAPR:NASDAQ) Deramiocel targets FDA approval by August 2026, with analysts issuing Buy ratings and price targets as high as US$60.New Alzheimer's Imaging Push Expands as Financing Terms Get Investor-Friendly
Grey Matters Health Inc. (GREY:CSE; AGW0:FRA; AGNPF:OTCQB) amended warrant terms tied to its CA$1 million private placement as it advances plans for a U.S. brain-specific neuroimaging clinic focused on Alzheimer's diagnostics.Biopharma Company Reveals High-Impact SCI Recovery Gains
NervGen Pharma Corp. (NGEN:TSX.V; NGENF:OTCQX) reports 100% responder rates for NVG-291 in spinal cord injury trials, strengthening hopes for major recovery breakthroughs.200 Brain PET Scans, 162 Alzheimer's Drugs: A Diagnostic Push Takes Shape
Grey Matters Health Inc. (GREY:CSE; AGW0:FRA; AGNPF:OTCQB) signed an LOI tied to a minimum of 200 brain PET scans for an Alzheimer's clinical trial while expanding its NovaScan neuroimaging strategy.Cleantech Co. Wins PFAS Deal, Engineering Pact, Ships Clyra
Research Report
BioLargo (BLGO:OTCQX) shipped Clyra's first stocking order, signed Aquatech PFAS MOU, and won a US$1.2M engineering contract for a minerals processing facility, according to an Oak Ridge Financial research note Lexington, MA Biopharma Co. Reports Q1 2026 Financials, Makes R&D Plans
Keros Therapeutics Inc. (KROS:NASDAQ) lowered research spending & reported funding through 2028 as analysts monitor upcoming trial catalysts for ALS & Muscular Dystrophy drugs.Lexington, MA Biotech Pushes DMD Phase 2 Start to 3Q26 on Regulatory Hurdles
Research Report
Keros Therapeutics (KROS:NASDAQ) disclosed that initiation of its Phase 2 rinvatercept study in Duchenne muscular dystrophy will slip from 2Q26 to 3Q26 due to procedural regulatory delays, according to a Wedbush research note. 
Streetwise Key Charts
